Health-related quality of life and symptom burden in patients with melanoma during and after immune checkpoint inhibitor therapy - a pilot study.

BMC Cancer · 2025 · PMC12532475 · PMID 41102719

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Comparison of the treatment and survivor group The disparity in HRQoL between our two groups was small and did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.